References

1.

Abaci O, Arat Ozkan A, Kocas C, et al. Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography. Am J Cardiol. 2015 Apr 1;115(7):867–71. [PubMed: 25670636]

2.

Acikel S, Muderrisoglu H, Yildirir A, et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis. 2010 Dec;21(8):750–7. [PubMed: 20962623]

3.

Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011 Sep 13;124(11):1250–9. [PubMed: 21859972]

4.

Albabtain MA, Almasood A, Alshurafah H, et al. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-induced nephropathy: A prospective randomized study. Journal of Interventional Cardiology. 2013;26(1):90–6. [PubMed: 22994682]

5.

Alexopoulos E, Spargias K, Kyrzopoulos S, et al. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media. Am J Med Sci. 2010 Jan;339(1):25–30. [PubMed: 19996728]

6.

Alioglu E, Saygi S, Turk U, et al. N-acetylcysteine in preventing contrast-induced nephropathy assessed by cystatin C. Cardiovasc Ther. 2013 Jun;31(3):168–73. [PubMed: 22212518]

7.

Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002 Nov;57(3):279–83. [PubMed: 12410497]

8.

Amini M, Salarifar M, Amirbaigloo A, et al. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. Trials. 2009;10:45. [PMC free article: PMC2714294] [PubMed: 19563648]

9.

Aslanger E, Uslu B, Akdeniz C, et al. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Coron Artery Dis. 2012 Jun;23(4):265–70. [PubMed: 22343798]

10.

Awal A, Ahsan SA, Siddique MA, et al. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention. Mymensingh Med J. 2011 Apr;20(2):264–9. [PubMed: 21522098]

11.

Azmus AD, Gottschall C, Manica A, et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol. 2005 Feb;17(2):80–4. [PubMed: 15687530]

12.

Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003 Jun 18;41(12):2114–8. [PubMed: 12821233]

13.

Baskurt M, Okcun B, Abaci O, et al. N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy. Eur J Clin Invest. 2009 Sep;39(9):793–9. [PubMed: 19500141]

14.

Baranska-Kosakowska A, Zakliczynski M, Przybylski R, et al. Role of N-Acetylcysteine on Renal Function in Patients After Orthotopic Heart Transplantation Undergoing Coronary Angiography. Transplantation Proceedings. 2007;39(9):2853–5. [PubMed: 18022000]

15.

Beyazal H, Caliskan Z, Utac C. Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy. Ren Fail. 2014 Apr;36(3):351–5. [PubMed: 24341598]

16.

Bilasy ME, Oraby MA, Ismail HM, et al. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures. J Interv Cardiol. 2012 Aug;25(4):404–10. [PubMed: 22612071]

17.

Boccalandro F, Amhad M, Smalling RW, et al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv. 2003 Mar;58(3):336–41. [PubMed: 12594698]

18.

Boscheri A, Weinbrenner C, Botzek B, et al. Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol. 2007 Nov;68(5):279–86. [PubMed: 18044259]

19.

Boucek P, Havrdova T, Oliyarnyk O, et al. Prevention of contrast-induced nephropathy in diabetic patients with impaired renal function: A randomized, double blind trial of sodium bicarbonate versus sodium chloride-based hydration. Diabetes Res Clin Pract. 2013 Sep;101(3):303–8. [PubMed: 23835495]

20.

Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008 Sep 3;300(9):1038–46. [PubMed: 18768415]

21.

Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002 Jul 17;40(2):298–303. [PubMed: 12106935]

22.

Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007 Mar 13;115(10):1211–7. [PubMed: 17309916]

23.

Brueck M, Cengiz H, Hoeltgen R, et al. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial. J Invasive Cardiol. 2013 Jun;25(6):276–83. [PubMed: 23735352]

24.

Burns KE, Priestap F, Martin C. N-acetylcysteine in critically ill patients undergoing contrast-enhanced computed tomography: a randomized trial. Clin Nephrol. 2010 Oct;74(4):323–6. [PubMed: 20875388]

25.

Buyukhatipoglu H, Sezen Y, Yildiz A, et al. N-acetylcysteine fails to prevent renal dysfunction and oxidative stress after noniodine contrast media administration during percutaneous coronary interventions. Pol Arch Med Wewn. 2010 Oct;120(10):383–9. [PubMed: 20980943]

26.

Carbonell N, Blasco M, Sanjuan R, et al. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. Int J Cardiol. 2007 Jan 31;115(1):57–62. [PubMed: 16814414]

27.

Carbonell N, Sanjuan R, Blasco M, et al. N-acetylcysteine: short-term clinical benefits after coronary angiography in high-risk renal patients. Rev Esp Cardiol. 2010 Jan;63(1):12–9. [PubMed: 20089221]

28.

Castini D, Lucreziotti S, Bosotti L, et al. Prevention of contrast-induced nephropathy: a single center randomized study. Clin Cardiol. 2010 Mar;33(3):E63–8. [PMC free article: PMC6653091] [PubMed: 20127900]

29.

Chousterman BG, Bouadma L, Loric S, et al. Prevention of contrast induced nephropathy (CIN) by N-acetylcystein (NAC) : Different definitions, Different results. Intensive Care Medicine. 2011;37:S49.

30.

Chousterman BG, Bouadma L, Moutereau S, et al. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results. J Crit Care. 2013 Oct;28(5):701–9. [PubMed: 23683568]

31.

Demir M, Kutlucan A, Akin H, et al. Comparison of different agents on radiographic contrast agent induced nephropathy. European Journal of General Medicine. 2008;5(4):222–7.

32.

Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002 Dec;62(6):2202–7. [PubMed: 12427146]

33.

Dvorsak B, Kanic V, Ekart R, et al. Ascorbic Acid for the prevention of contrast-induced nephropathy after coronary angiography in patients with chronic renal impairment: a randomized controlled trial. Ther Apher Dial. 2013 Aug;17(4):384–90. [PubMed: 23931876]

34.

Erturk M, Uslu N, Gorgulu S, et al. Does intravenous or oral high-dose N-acetylcysteine in addition to saline prevent contrast-induced nephropathy assessed by cystatin C? Coron Artery Dis. 2014 Mar;25(2):111–7. [PubMed: 24365793]

35.

Ferrario F, Barone MT, Landoni G, et al. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study. Nephrol Dial Transplant. 2009 Oct;24(10):3103–7. [PubMed: 19549691]

36.

Frank H, Werner D, Lorusso V, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol. 2003 Sep;60(3):176–82. [PubMed: 14524580]

37.

Fung JW, Szeto CC, Chan WW, et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis. 2004 May;43(5):801–8. [PubMed: 15112170]

38.

Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004 Feb;25(3):212–8. [PubMed: 14972421]

39.

Gomes VO, Poli de Figueredo CE, Caramori P, et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart. 2005 Jun;91(6):774–8. [PMC free article: PMC1768952] [PubMed: 15894775]

40.

Gomes VO, Lasevitch R, Lima VC, et al. Hydration with sodium bicarbonate does not prevent contrast nephropathy: a multicenter clinical trial. Arq Bras Cardiol. 2012 Dec;99(6):1129–34. [PubMed: 23184077]

41.

Gulel O, Keles T, Eraslan H, et al. Prophylactic acetylcysteine usage for prevention of contrast nephropathy after coronary angiography. J Cardiovasc Pharmacol. 2005 Oct;46(4):464–7. [PubMed: 16160598]

42.

Gunebakmaz O, Kaya MG, Koc F, et al. Does nebivolol prevent contrast-induced nephropathy in humans? Clin Cardiol. 2012 Apr;35(4):250–4. [PMC free article: PMC6652354] [PubMed: 22262230]

43.

Han S, Li XM, Mohammed Ali LA, et al. Effect of short-term different statins loading dose on renal function and CI-AKI incidence in patients undergoing invasive coronary procedures. Int J Cardiol. 2013 Oct 12;168(5):5101–3. [PubMed: 23972962]

44.

Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014 Jan 7-14;63(1):62–70. [PubMed: 24076297]

45.

Heguilen RM, Liste AA, Payaslian M, et al. N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial. Clin Exp Nephrol. 2013 Jun;17(3):396–404. [PubMed: 23138396]

46.

Holscher B, Heitmeyer C, Fobker M, et al. Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol. 2008 Nov;24(11):845–50. [PMC free article: PMC2644537] [PubMed: 18987758]

47.

Hsu CH, Lee JD, Lo PH, et al. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine after cardiac angiography in diabetic patients with renal dysfunction. Mid-Taiwan Journal of Medicine. 2007;12(4):173–83.

48.

Hsu TF, Huang MK, Yu SH, et al. N-acetylcysteine for the prevention of contrast-induced nephropathy in the emergency department. Intern Med. 2012;51(19):2709–14. [PubMed: 23037460]

49.

Izani Wan Mohamed WM, Darus Z, Yusof Z. Oral N-acetylcysteine in prevention of contrast induced nephropathy following coronary angiogram. International Medical Journal. 2008;15(5):353–61.

50.

Jaffery Z, Verma A, White CJ, et al. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. Catheter Cardiovasc Interv. 2012 May 1;79(6):921–6. [PubMed: 21542122]

51.

Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study. Am Heart J. 2008 Mar;155(3):499 e1–8. [PubMed: 18294484]

52.

Jo SH, Koo BK, Park JS, et al. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Am Heart J. 2009 Mar;157(3):576–83. [PubMed: 19249432]

53.

Jo SH, Hahn JY, Lee SY, et al. High-dose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention. J Cardiovasc Med (Hagerstown). 2014 Jul 16; [PubMed: 25032713]

54.

Kama A, Yilmaz S, Yaka E, et al. Comparison of short-term infusion regimens of N-acetylcysteine plus intravenous fluids, sodium bicarbonate plus intravenous fluids, and intravenous fluids alone for prevention of contrast-induced nephropathy in the emergency department. Acad Emerg Med. 2014 Jun;21(6):615–22. [PubMed: 25039544]

55.

Katoh H, Nozue T, Kimura Y, et al. Elevation of urinary liver-type fatty acid-binding protein as predicting factor for occurrence of contrast-induced acute kidney injury and its reduction by hemodiafiltration with blood suction from right atrium. Heart and Vessels. 2014;29(2):191–7. [PubMed: 23604313]

56.

Kaya A, Kurt M, Tanboga IH, et al. Rosuvastatin versus Atorvastatin to prevent Contrast induced Nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-CIN trial). Acta Cardiologica. 2013;68(5):488–94. [PubMed: 24283110]

57.

Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003 Feb 5;289(5):553–8. [PubMed: 12578487]

58.

Kefer JM, Hanet CE, Boitte S, et al. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol. 2003 Dec;58(6):555–60. [PubMed: 14713182]

59.

Khalili H, Dashti-Khavidaki S, Tabifar H, et al. N-acetylcysteine in the prevention of contrast agent-induced nephrotoxicity in patients undergoing computed tomography studies. Therapy. 2006;3(6):773–7.

60.

Kim BJ, Sung KC, Kim BS, et al. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial. Int J Cardiol. 2010 Feb 4;138(3):239–45. [PubMed: 18793808]

61.

Kimmel M, Butscheid M, Brenner S, et al. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc - Preliminary results. Nephrology Dialysis Transplantation. 2008;23(4):1241–5. [PubMed: 18174269]

62.

Kinbara T, Hayano T, Ohtani N, et al. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy. J Cardiol. 2010 Mar;55(2):174–9. [PubMed: 20206069]

63.

Koc F, Ozdemir K, Kaya MG, et al. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial. Int J Cardiol. 2012 Mar 22;155(3):418–23. [PubMed: 21106264]

64.

Koc F, Ozdemir K, Altunkas F, et al. Sodium bicarbonate versus isotonic saline for the prevention of contrast-induced nephropathy in patients with diabetes mellitus undergoing coronary angiography and/or intervention: A multicenter prospective randomized study. Journal of Investigative Medicine. 2013;61(5):872–7. [PubMed: 23552179]

65.

Kooiman J, Sijpkens YW, de Vries JP, et al. A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography. Nephrol Dial Transplant. 2014 May;29(5):1029–36. [PubMed: 24578471]

66.

Kotlyar E, Keogh AM, Thavapalachandran S, et al. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial. Heart Lung Circ. 2005 Dec;14(4):245–51. [PubMed: 16360994]

67.

Kumar A, Bhawani G, Kumari N, et al. Comparative study of renal protective effects of allopurinol and N-acetyl-cysteine on contrast induced nephropathy in patients undergoing cardiac catheterization. J Clin Diagn Res. 2014 Dec;8(12):HC03–7. [PMC free article: PMC4316271] [PubMed: 25653965]

68.

Lawlor DK, Moist L, DeRose G, et al. Prevention of contrast-induced nephropathy in vascular surgery patients. Ann Vasc Surg. 2007 Sep;21(5):593–7. [PubMed: 17823041]

69.

Lee SW, Kim WJ, Kim YH, et al. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial). Am J Cardiol. 2011 May 15;107(10):1447–52. [PubMed: 21420063]

70.

Lehnert T, Keller E, Gondolf K, et al. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant. 1998 Feb;13(2):358–62. [PubMed: 9509446]

71.

Leoncini M, Toso A, Maioli M, et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014 Jan 7-14;63(1):71–9. [PubMed: 24076283]

72.

Li W, Fu X, Wang Y, et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012;122(3):195–202. [PubMed: 22854323]

73.

Li H, Li X, Ma H, et al. Atorvastatin combining with probucol: A new way to reduce serum uric acid level during perioperative period of interventional procedure. The Scientific World Journal. 2014;2014 ((Li H., rainbow-li-313@163.com) Graduate School, Tianjin Medical University, Tianjin 300051, China). [PMC free article: PMC3929062] [PubMed: 24672331]

74.

Liu Y, Liu YH, Tan N, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention. PLoS One. 2014;9(10):e111124. [PMC free article: PMC4214705] [PubMed: 25357250]

75.

MacNeill BD, Harding SA, Bazari H, et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv. 2003 Dec;60(4):458–61. [PubMed: 14624421]

76.

Manari A, Magnavacchi P, Puggioni E, et al. Acute kidney injury after primary angioplasty: effect of different hydration treatments. J Cardiovasc Med (Hagerstown). 2014 Jan;15(1):60–7. [PubMed: 24500238]

77.

Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003 Oct 2;349(14):1333–40. [PubMed: 14523141]

78.

Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006 Jun 29;354(26):2773–82. [PubMed: 16807414]

79.

Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med. 2006 Feb;119(2):155–62. [PubMed: 16443418]

80.

Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol. 2007 Sep 1;100(5):781–6. [PubMed: 17719320]

81.

Matejka J, Varvarovsky I, Vojtisek P, et al. Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. Heart Vessels. 2010 Nov;25(6):536–42. [PubMed: 20878408]

82.

Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004 May 19;291(19):2328–34. [PubMed: 15150204]

83.

Miner SE, Dzavik V, Nguyen-Ho P, et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004 Oct;148(4):690–5. [PubMed: 15459602]

84.

Motohiro M, Kamihata H, Tsujimoto S, et al. A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Am J Cardiol. 2011 Jun 1;107(11):1604–8. [PubMed: 21420053]

85.

Ochoa A, Pellizzon G, Addala S, et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. Journal of Interventional Cardiology. 2004:159–65. [PubMed: 15209578]

86.

Oldemeyer JB, Biddle WP, Wurdeman RL, et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003 Dec;146(6):E23. [PubMed: 14661012]

87.

Ozcan EE, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007 Sep;154(3):539–44. [PubMed: 17719303]

88.

Ozhan H, Erden I, Ordu S, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010 Oct;61(7):711–4. [PubMed: 20395226]

89.

Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial. Am J Cardiol. 2011 Jul 1;108(1):1–7. [PubMed: 21529740]

90.

Poletti PA, Saudan P, Platon A, et al. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol. 2007 Sep;189(3):687–92. [PubMed: 17715118]

91.

Qiao B, Deng J, Li Y, et al. Rosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction. Int J Clin Exp Med. 2015;8(2):2342–9. [PMC free article: PMC4402818] [PubMed: 25932171]

92.

Quintavalle C, Fiore D, De Micco F, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012 Dec 18;126(25):3008–16. [PubMed: 23147173]

93.

Ratcliffe JA, Thiagarajah P, Chen J, et al. Prevention of contrast-induced nephropathy: A randomized controlled trial of sodium bicarbonate and N-acetylcysteine. International Journal of Angiology. 2009;18(4):193–7. [PMC free article: PMC2903033] [PubMed: 22477552]

94.

Rashid ST, Salman M, Myint F, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004 Dec;40(6):1136–41. [PubMed: 15622367]

95.

Reinecke H, Fobker M, Wellmann J, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. Clin Res Cardiol. 2007 Mar;96(3):130–9. [PubMed: 17180572]

96.

Sadat U, Walsh SR, Norden AG, et al. Does oral N-acetylcysteine reduce contrast-induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography? A randomized-controlled study. Angiology. 2011 Apr;62(3):225–30. [PubMed: 20682612]

97.

Sandhu C, Belli AM, Oliveira DB. The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity. Cardiovasc Intervent Radiol. 2006 May-Jun;29(3):344–7. [PubMed: 16502177]

98.

Sanei H, Hajian-Nejad A, Sajjadieh-Kajouei A, et al. Short term high dose atorvastatin for the prevention of contrast-induced nephropathy in patients undergoing computed tomography angiography. ARYA Atheroscler. 2014;10(5) [PMC free article: PMC4251479] [PubMed: 25477982]

99.

Sar F, Saler T, Ecebay A, et al. The efficacy of n-acetylcysteine in preventing contrast-induced nephropathy in type 2 diabetic patients without nephropathy. J Nephrol. 2010 Jul-Aug;23(4):478–82. [PubMed: 20383874]

100.

Seyon RA, Jensen LA, Ferguson IA, et al. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention. Heart Lung. 2007 May-Jun;36(3):195–204. [PubMed: 17509426]

101.

Shavit L, Korenfeld R, Lifschitz M, et al. Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. J Interv Cardiol. 2009 Dec;22(6):556–63. [PubMed: 19732281]

102.

Shehata M, Hamza M. Impact of High Loading Dose of Atorvastatin in Diabetic Patients with Renal Dysfunction Undergoing Elective Percutaneous Coronary Intervention: A Randomized Controlled Trial. Cardiovascular Therapeutics. 2015;33(2):35–41. [PubMed: 25677920]

103.

Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110(18):2837–42. [PubMed: 15492300]

104.

Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002 Oct 16;40(8):1383–8. [PubMed: 12392825]

105.

Tanaka A, Suzuki Y, Suzuki N, et al. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction? Intern Med. 2011;50(7):673–7. [PubMed: 21467697]

106.

Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000 Jul 20;343(3):180–4. [PubMed: 10900277]

107.

Thayssen P, Lassen JF, Jensen SE, et al. Prevention of contrast-induced nephropathy with n-acetylcysteine or sodium bicarbonate in patients with st-segment-myocardial infarction a prospective, randomized, open-labeled trial. Circulation: Cardiovascular Interventions. 2014;7(2):216–24. [PubMed: 24714489]

108.

Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol. 2010 May 18;55(20):2201–9. [PubMed: 20466200]

109.

Toso A, Maioli M, Leoncini M, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010 Feb 1;105(3):288–92. [PubMed: 20102936]

110.

Traub SJ, Mitchell AM, Jones AE, et al. N-acetylcysteine plus intravenous fluids versus intravenous fluids alone to prevent contrast-induced nephropathy in emergency computed tomography. Ann Emerg Med. 2013 Nov;62(5):511–20 e25. [PubMed: 23769807]

111.

Ueda H, Yamada T, Masuda M, et al. Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures. Am J Cardiol. 2011 Apr 15;107(8):1163–7. [PubMed: 21349483]

112.

Vasheghani-Farahani A, Sadigh G, Kassaian SE, et al. Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial. J Nephrol. 2010 Mar-Apr;23(2):216–23. [PubMed: 20175053]

113.

Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med. 2001 Dec 15;111(9):692–8. [PubMed: 11747848]

114.

Wang JH, Subeq YM, Tsai WC, et al. Intravenous N-acetylcysteine with saline hydration improves renal function and ameliorates plasma total homocysteine in patients undergoing cardiac angiography. Renal Failure. 2008;30(5):527–33. [PubMed: 18569934]

115.

Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004 Sep;148(3):422–9. [PubMed: 15389228]

116.

Xinwei J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009 Aug 15;104(4):519–24. [PubMed: 19660605]

117.

Yeganehkhah MR, Iranirad L, Dorri F, et al. Comparison between three supportive treatments for prevention of contrast-induced nephropathy in high-risk patients undergoing coronary angiography. Saudi J Kidney Dis Transpl. 2014 Nov;25(6):1217–23. [PubMed: 25394438]

118.

Yun KH, Lim JH, Hwang KB, et al. Effect of high dose rosuvastatin loading before percutaneous coronary intervention on contrast-induced nephropathy. Korean Circulation Journal. 2014;44(5):301–6. [PMC free article: PMC4180606] [PubMed: 25278982]

119.

Zhang J, Li Y, Tao GZ, et al. Short-term rosuvastatin treatment for the prevention of contrast-induced acute kidney injury in patients receiving moderate or high volumes of contrast media: a sub-analysis of the TRACK-D study. Chin Med J (Engl). 2015 Mar 20;128(6):784–9. [PMC free article: PMC4833983] [PubMed: 25758273]

120.

Zhou L, Chen H. Prevention of contrast-induced nephropathy with ascorbic acid. Intern Med. 2012;51(6):531–5. [PubMed: 22449658]

121.

Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology. 2002 Jun;223(3):772–9. [PubMed: 12034949]

122.

Heng AE, Cellarier E, Aublet-Cuvelier B, et al. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date? Clin Nephrol. 2008 Dec;70(6):475–84. [PubMed: 19049703]

123.

Staniloae CS, Doucet S, Sharma SK, et al. N-acetylcysteine added to volume expansion with sodium bicarbonate does not further prevent contrast-induced nephropathy: Results from the cardiac angiography in renally impaired patients study. Journal of Interventional Cardiology. 2009;22(3):261–5. [PubMed: 19490358]

124.

Tamura A, Goto Y, Miyamoto K, et al. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol. 2009 Oct 1;104(7):921–5. [PubMed: 19766757]

125.

Vasheghani-Farahani A, Sadigh G, Kassaian SE, et al. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009 Oct;54(4):610–8. [PubMed: 19619921]

126.

Briguori C, Visconti G, Focaccio A, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011 Sep 13;124(11):1260–9. [PubMed: 21844075]

127.

Cho R, Javed N, Traub D, et al. Oral hydration and alkalinization is noninferior to intravenous therapy for prevention of contrast-induced nephropathy in patients with chronic kidney disease. J Interv Cardiol. 2010 Oct;23(5):460–6. [PubMed: 20796166]

128.

Hafiz AM, Jan MF, Mori N, et al. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies. Catheter Cardiovasc Interv. 2012 May 1;79(6):929–37. [PubMed: 21542114]

129.

Klima T, Christ A, Marana I, et al. Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. Eur Heart J. 2012 Aug;33(16):2071–9. [PubMed: 22267245]

130.

Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008 Aug 19;52(8):599–604. [PubMed: 18702961]

131.

Maioli M, Toso A, Leoncini M, et al. Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial. Circ Cardiovasc Interv. 2011 Oct 1;4(5):456–62. [PubMed: 21972403]

132.

Pakfetrat M, Nikoo MH, Malekmakan L, et al. A comparison of sodium bicarbonate infusion versus normal saline infusion and its combination with oral acetazolamide for prevention of contrast-induced nephropathy: a randomized, double-blind trial. Int Urol Nephrol. 2009;41(3):629–34. [PubMed: 19137409]

133.

Schmidt P, Pang D, Nykamp D, et al. N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography. Ann Pharmacother. 2007 Jan;41(1):46–50. [PubMed: 17190844]

134.

Adolph E, Holdt-Lehmann B, Chatterjee T, et al. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis. 2008 Sep;19(6):413–9. [PubMed: 18955835]